BGR GOVERNMENT AFFAIRS

Lobbying for ALKERMES, INC. · Biopharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.